We develop precision genome engineering approaches to study the role that genetic mutations play in the initiation of cancers and their resistance to therapies.
New preprint together with @boettcher_lab! El Kassem et al: Targeted Perturb-seq Reveals EGR1 and FOS as Key Regulators of the Transcriptional RAF-MAPK Response https://t.co/rOuAiyeQw4
Zusammenrücken, Kooperations-Potentiale aufdecken & wissenschaftlichen #Nachwuchs sichtbar machen: Mehr als 200 Teilnehmende nutzten den 8. #Forschungstag der Medizinischen Fakultät @unimedhal@UniHalle, um die Ergebnisse ihrer #Forschung zu präsentieren.
https://t.co/fb8lKnvLTF
We are recruiting! If you're interested in a PhD in the field of cancer research with a focus on drug target discovery using CRISPR technologies, please apply. More information at https://t.co/zOESfWXaOl
Our first study using scRNA-seq to analyse how individual cells decide to inactivate one or the other X chromosome at the onset of random X inactivation. Great collaboration with @lisamar2017, led by first author Guido Pacini. https://t.co/NSFTx7P5lZ A thread
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K | Beautiful work by Mikolaj Slabicki and friends – great to see how enthusiasm for science and team spirit have paid off! @DKFZ @NCT_HD @biomiko https://t.co/Z4whbANaIH
"Among my academic colleagues, I have observed a common response to the Covid-19 crisis. They are fighting valiantly for a sense of normalcy. I wish anyone who pursues that path the best of luck."
https://t.co/CkcxW1sU0e